View clinical trials related to Financial Toxicity.
Filter by:During the immune checkpoint inhibitor therapy (ICIT), most of the patients stay at home, but there is lacking of the studies to explore their physical and psychological distress, financial toxicity, care needs, and quality of life. Therefore, the aims of this program are to (1) explore the immune-related adverse event (irAE) severity, distress, financial toxicity, and quality of life and examine the psychometric testing of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM); (2) establish the LINE group for assessing irAE severity and change trajectory of quality of life in one-year follow-up and (3) combined retrospective chart review and the finding in aim (2) to develop the risk prediction model in order to identify the high risk population.
The goal of this pilot study is to access the feasibility and impact of a financial navigation program on improving financial toxicity among patients with breast cancer in China. The main questions it aims to answer are: - Is the intervention feasible and acceptable among participants? - Does the intervention enhance participants' cost-related health literacy? - Does the intervention reduce participants' financial toxicity? Researchers will compare the financial navigation program with usual oncology care to preliminarily evaluate its effectiveness. Participants will receive comprehensive information support, including: - Strategies on patient-physician costs discussion - Skills for inquiring and tracking treatment-related costs - Basic knowledge about health insurance - Guidance on accessing and applying for financial assistance - Suggestions for returning to normal life and work - Strategies for holding a financial-related family meeting
Objectives: - Assess the extent of financial burden of patients undergoing radiotherapy - Identify clinical and socio-economical factors correlated with the occurrence and extent of financial toxicity - Design a structured social consultation to reduce financial burden induced by radiotherapy Inclusion criteria: 1. age ≥ 18 years of age 2. indication for radiation treatment of a malignant disease 3. Karnofsky Performance score (KPS) ≥ 70% 4. Life expectancy ≥ 3 months Exclusion criteria: 1. Inability to provide informed consent 2. Inability to attend study visits and fulfill data collection requirements 3. Simultaneous participation in other studies which could interfere with this study Primary outcome: Financial burden as expressed by the COST score, measured at baseline and 3 months after completion of radiotherapy Secondary outcomes: - Socio-Economic factors at baseline - Health-related quality of life (EORTC QLQ-C30) at baseline and 3 months - Depression (PHQ-9) at baseline and 3 months - Coping mechanisms to address financial burden Primary Endpoint: Influence of secondary outcomes on changes of the primary outcome (COST-Score) between baseline and 3 months. Secondary Endpoints: - Changes in the COST-Score over time - Changes in PHQ-9 over time - Changes in EORTC QLQ-C30 over time This is an exploratory pilot study. To assess the compliance and effectiveness of the used methods all patients willing to participate in the given time period will be enrolled. To be assessed for eligibility: n = 300 To be allocated/randomised (if applicable) to trial: n = 150 To be analysed: n = 120
The DISCO App is designed to improve, during the interaction, patient active participation and patient-initiated oncologist treatment cost discussions, and, in the short term, patient's treatment cost knowledge, self-efficacy for managing both cost and physician interactions, referrals, perceived financial toxicity (i.e., distress and material hardship); in turn, these will affect longer-term outcomes of financial toxicity and adherence.